Gustave Roussy and THERYQ: France Welcomes the First FLASH Radiotherapy Machine to Treat Patients

Gustave Roussy and THERYQ announce a strategic and structuring partnership to roll out and assess FLASH technology for radiotherapy. French medical technology company THERYQ, specializing in particle accelerators and radiotherapy systems, has provided Gustave Roussy’s Department of Radiotherapy with the first FLASH clinical radiotherapy machine in France for treating superficial tumours.

The collaboration between Gustave Roussy, Europe’s leading cancer centre, ranking third worldwide, and THERYQ, a French company specializing in the manufacture of FLASH radiotherapy systems, represents a major breakthrough in cancer treatment in France through the arrival of the first FLASHKNiFE® machine.

FLASHKNiFE® technology is a new radiotherapy process that uses electrons. The FLASH radiotherapy system delivers a very high dose rate, enabling professionals to treat patients in milliseconds. Several pre-clinical studies have shown that this technique can further save healthy tissue while effectively destroying tumour cells. In addition, the very short irradiation time eliminates any movement of the organ or tumour, ensuring more precise and controlled targeting.

Thanks to this major partnership, Gustave Roussy will be the first centre in France to use THERYQ’s FLASH radiotherapy machine. Prior to its mainstream use, a clinical study will be conducted to evaluate the effectiveness of FLASH radiotherapy in skin cancer patients. The results of this study could have a significant impact on skin cancer management, thereby paving the way for new therapeutic breakthroughs, including in the treatment of all solid tumours.

Professor Eric Deutsch, Head of Gustave Roussy’s Department of Radiotherapy, said: “Introducing this system will allow FLASH radiation therapy, a significant evolution from current methods, to undergo thorough clinical testing. The reduced number of sessions, along with the possibility of minimizing radiation-induced side effects, will lead to more tolerable and effective treatments. We are fully invested in and motivate by this project, which fuels the hope of significantly improving therapeutic management.”

Mr. Ludovic Le Meunier, CEO of THERYQ, added: “We are delighted to work with Gustave Roussy, a pioneer in cancer research and treatment, to introduce FLASH radiation therapy in France. This collaboration marks a key milestone in our goal to deliver advanced treatment solutions to patients. FLASH radiotherapy has tremendous potential to improve skin cancer patient management and we look forward to this study’s results.”

Gustave Roussy and THERYQ are committed to pursuing their joint effort to develop innovative treatments for the benefit of patients, leading to more effective and tolerable radiotherapy thanks to this promising technology.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”